Wang Gui, Yang Chenghui, Zeng Donglin, Wang Jihao, Mao Huaxin, Xu Yu, Jiang Chao, Wang Zhen
Department of General Surgery, Longquan People's Hospital, Lishui, China.
Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Front Pharmacol. 2024 Feb 22;15:1332574. doi: 10.3389/fphar.2024.1332574. eCollection 2024.
Breast squamous cell carcinoma (SCC) is an uncommon and highly aggressive variant of metaplastic breast cancer. Despite its rarity, there is currently no consensus on treatment guidelines for this specific subtype. Previous studies have demonstrated that chemotherapy alone has limited efficacy in treating breast SCC. However, the potential for targeted therapy in combination with chemotherapy holds promise for future treatment options. In this case report, we present a patient with advanced HER2-positive breast SCC, exhibiting a prominent breast mass, localized ulcers, and metastases in the lungs and brain. Our treatment approach involved the administration of HER2-targeted drugs in conjunction with paclitaxel, resulting in a sustained control of tumor growth. This case represents a rare occurrence of HER2-positive breast SCC, with limited available data on the efficacy of previous HER2-targeted drugs in treating such patients. Our study presents the first application of HER2-targeted drugs in this particular case, offering novel therapeutic insights for future considerations. Additionally, it is imperative to conduct further investigations to assess the feasibility of treatment options in a larger cohort of patients.
乳腺鳞状细胞癌（SCC）是一种罕见且侵袭性很强的化生性乳腺癌亚型。尽管其罕见，但目前对于这种特定亚型的治疗指南尚无共识。先前的研究表明，单纯化疗在治疗乳腺SCC方面疗效有限。然而，靶向治疗联合化疗的潜力为未来的治疗选择带来了希望。在本病例报告中，我们介绍了一名患有晚期HER2阳性乳腺SCC的患者，其表现为明显的乳房肿块、局部溃疡以及肺和脑转移。我们的治疗方法包括给予HER2靶向药物联合紫杉醇，从而实现了对肿瘤生长的持续控制。该病例代表了罕见的HER2阳性乳腺SCC，关于先前HER2靶向药物治疗此类患者的疗效，可用数据有限。我们的研究展示了HER2靶向药物在这一特殊病例中的首次应用，为未来的考量提供了新的治疗见解。此外，必须进行进一步研究，以评估在更大患者队列中治疗方案的可行性。
